Drug Profile
LPX EWS/FL1 T1
Alternative Names: Bi-shRNAEWS-FLI-Type-1-LPX; pbi-functional short hairpin RNA EWS/FLI2 type 1 lipoplex; pbi-functional shRNA EWS-FLI2 type 1 lipoplex; pbi-shRNA™ EWS/FLI1 Type 1 LPXLatest Information Update: 26 Jul 2023
Price :
$50
*
At a glance
- Originator Gradalis
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ewing's sarcoma
Most Recent Events
- 26 Jul 2023 Phase I development is ongoing in Ewing's Sarcoma (In adolescents, In children, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV, Infusion) (NCT02736565)
- 01 Mar 2023 Gradalis completes a phase I trial in Ewing's Sarcoma (Late-stage disease, Second-line therapy or greater, In children, In adolescents, In adults) in USA (IV) (NCT02736565)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Ewing's Sarcoma(In adolescents, In children, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV, Infusion)